Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

NCT02735239 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Oxaliplatin
DRUG: Capecitabine
RADIATION: Radiotherapy
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: 5-fluorouracil (5-FU)
DRUG: Leucovorin
DRUG: Docetaxel

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]